Dasatinib

Generic Name
Dasatinib
Brand Names
Sprycel
Drug Type
Small Molecule
Chemical Formula
C22H26ClN7O2S
CAS Number
302962-49-8
Unique Ingredient Identifier
X78UG0A0RN
Background

Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication

Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

A Study to Investigate the Safety and Efficacy of KQB198 As Monotherapy and in Combination in Participants with Advanced Hematologic Malignancies

Phase 1
Recruiting
Conditions
Hematologic Malignancies
Adult
Interventions
Drug: KQB198
Drug: Dasatinib
First Posted Date
2024-10-17
Last Posted Date
2024-12-05
Lead Sponsor
Kumquat Biosciences Inc.
Target Recruit Count
122
Registration Number
NCT06645886
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Colorado Blood Cancer Institute, Denver, Colorado, United States

๐Ÿ‡บ๐Ÿ‡ธ

Oncology Hematology Cincinnati, Cincinnati, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Texas Oncology Austin Central, Austin, Texas, United States

and more 4 locations

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date
2024-08-01
Last Posted Date
2024-11-08
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
128
Registration Number
NCT06533748
Locations
๐Ÿ‡บ๐Ÿ‡ธ

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

First Posted Date
2024-04-30
Last Posted Date
2024-12-16
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
145
Registration Number
NCT06390319
Locations
๐Ÿ‡บ๐Ÿ‡ธ

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

First Posted Date
2024-04-09
Last Posted Date
2024-07-08
Lead Sponsor
Fudan University
Target Recruit Count
10
Registration Number
NCT06355037
Locations
๐Ÿ‡จ๐Ÿ‡ณ

270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China

Ma-Spore ALL 2020 Study

First Posted Date
2024-03-28
Last Posted Date
2024-03-28
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
500
Registration Number
NCT06336395
Locations
๐Ÿ‡ฒ๐Ÿ‡พ

University Malaya Medical Centre, Kuala Lumpur, Malaysia

๐Ÿ‡ฒ๐Ÿ‡พ

Subang Jaya Medical Centre, Kuala Lumpur, Malaysia

๐Ÿ‡ธ๐Ÿ‡ฌ

KK Women's and Children's Hospital, Singapore, Singapore

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

First Posted Date
2023-11-09
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
680
Registration Number
NCT06124157

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

Phase 2
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Dasatinib
First Posted Date
2023-09-28
Last Posted Date
2024-10-07
Lead Sponsor
Institut Paoli-Calmettes
Target Recruit Count
35
Registration Number
NCT06055621
Locations
๐Ÿ‡ซ๐Ÿ‡ท

Institut Paoli Calmettes, Marseille, France

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

Phase 1
Recruiting
Conditions
Lymphoblastic Leukemia
Interventions
Drug: Dasatinib
First Posted Date
2023-08-15
Last Posted Date
2024-02-08
Lead Sponsor
Stanford University
Target Recruit Count
20
Registration Number
NCT05993949
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Stanford University, Palo Alto, California, United States

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

First Posted Date
2023-03-02
Last Posted Date
2024-06-21
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Target Recruit Count
26
Registration Number
NCT05751044
Locations
๐Ÿ‡ณ๐Ÿ‡ฑ

Princess Mรกxima Center for Pediatric Oncology, Utrecht, Netherlands

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

First Posted Date
2023-02-13
Last Posted Date
2023-02-21
Lead Sponsor
Oslo University Hospital
Target Recruit Count
40
Registration Number
NCT05725200
Locations
๐Ÿ‡ณ๐Ÿ‡ด

Oslo University Hospital, Oslo, Norway

ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy